New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake
PM360
JUNE 29, 2022
These low adoption rates highlight the need for more migraine-drug awareness and suggest that pharma marketers should explore new strategies to boost patient uptake. Other influencing factors included more information on side effects (36%), drug cost (28%), and efficacy (28%). Migraine Is Widespread, But Expertise Is Limited.
Let's personalize your content